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Abstract: 
Introduction: Influenza is responsible for serious illness, especially in elderly. It has short term morbidity as well as long term 
morbidity and mortality during the acute infection, recovery could be long and sometimes incomplete. This could lead to 
persistent decrease in health and function, involving catastrophic disability, which has acute complications on the well-being and 
support needs of older adults and their caregivers. This means that prevention of infection and effective management when 
illness has occurred are of great importance. 
This sets the stage for a discussion of newer influenza vaccine products that have been developed with the aim of improving 
vaccine effectiveness in older adults. We will highlight the importance of influenza prevention to support healthy aging, along 
with the need to improve vaccine coverage rates using available vaccine products, and to spur development of better influenza 
vaccines for older adults in the near future.  
Aim of work: In this review, we will discuss flu shot 
Methodology: We did a systematic search for flu shot using PubMed search engine (http://www.ncbi.nlm.nih.gov/) and Google 
Scholar search engine (https://scholar.google.com). All relevant studies were retrieved and discussed. We only included full 
articles. 
Conclusions: Elderly are susceptible to poor outcomes from influenza in short- and long-term. Both complications of acute 
illness and continued functional disability have major effects on the health and well-being of elderly and their families. So, 
prevention is of highly importat as to support healthy elderly. Though immune responses to vaccination could be less optimal in 
elderly, especially those who are weak, vaccination remains to be an important method in the prevention of severe outcomes from 
influenza. Many vaccines are available for older adults, including standard-dose trivalent and quadrivalent formulations of split 
virus and subunit vaccines, high-dose split-virus vaccine, adjuvanted subunit vaccine, and recombinant HA vaccine. Due to the 
relative qualities and availability of these products could change between jurisdictions, vaccinating with whatever proper and 
approved product is available continues to be a major recommendation; vaccination coverage continues to be less optimal in 
most states. As our understanding of immune changes with aging, and frailty progresses, vaccine products will perfectly be more 
tailored to generate optimal protection for this susceptible population 
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INTRODUCTION: 
Influenza is responsible for serious illness, especially 
in elderly. It has short term morbidity as well as long 
term morbidity and mortality during the acute 
infection, recovery could be long and sometimes 
incomplete. This could lead to persistent decrease in 
health and function, involving catastrophic disability, 
which has acute complications on the well-being and 
support needs of older adults and their caregivers. 
This means that prevention of infection and effective 
management when illness has occurred are of great 
importance. 
This sets the stage for a discussion of newer influenza 
vaccine products that have been developed with the 
aim of improving vaccine effectiveness in older 
adults. We will highlight the importance of influenza 
prevention to support healthy aging, along with the 
need to improve vaccine coverage rates using 
available vaccine products, and to spur development 
of better influenza vaccines for older adults in the 
near future.  
In this review, we will discuss the most recent 
evidence regarding flu shot. 
METHODOLOGY: 
We did a systematic search for flu shot using 
PubMed search engine 
(http://www.ncbi.nlm.nih.gov/) and Google Scholar 
search engine (https://scholar.google.com). All 
relevant studies were retrieved and discussed. We 
only included full articles. 
The terms used in the search were: flu shot, 
indication, elderly, recent updates, primary care. 
 
Influenza Can Have a Severe and Lasting Impact 
on Older Adults’ Health and Well‑Being 
Elderly people are excessively affected by influenza 
and its complications. In the acute-phase, morbidity 
and mortality are highest [1]. Globally, it is believed 
that more than two hundred thousand people suffer 
death from influenza and its respiratory 
complications yearly, of whom older adults age 75+ 
years are at the highest risk, with more than fifty 
deaths per 100,000 people aged 75+ years [2]. 
Remarkably, elderly people with severe illness need 
hospital admission. As an example, in the Canadian 
Serious Outcomes Surveillance (SOS) Network of 
acute care hospitals, more than 3394 adults were 
admitted to hospital with laboratory-confirmed 
influenza over three consecutive influenza seasons. 
At ten percent, mortality was high in the overall 
cohort, and increased with age [3]. Data from other 
national and international surveillance networks 
paints a similar picture of serious outcomes being 
more often experienced by elderly; this data 
contributed to international advisory body 
suggestions as discussed below. In spite of the 
severity of outcomes linked to influenza, and 
recommendations for vaccination for older adults and 
other high-risk groups in several states, vaccine 
coverage remains below the seventy five percent for 
the over 65 years population [4]. For example, in the 
US [5] and Canada, vaccination rates among elderly 
have remained to be the same and below seventy 
percent. In the European Union, influenza vaccine 
coverage in high-risk groups has decreased since 
2007; for those aged 65 + years, coverage varied 
widely across member states, with a median 
vaccination rate of around forty five percent [6]. 
 
It is becoming more apparent that longer-term 
complications are as well common. After an acute 
care hospitalization, a significant proportion of 
elderly will not go back to their baseline of health 
and functional status [7]. In the SOS Network, it is 
estimated that around nineteen percent of elderly 
aged 65 + years admitted with respiratory illness, 
involving laboratory-confirmed influenza, suffered 
catastrophic disability. Even elderly who are not 
hospitalized can suffer persistent decrease in function 
and prolonged recovery from influenza or influenza- 
like illness.  
 
Frailty is an important concept when it comes to 
elderly and influenza and can be estimated and 
defined in several ways. Generally, frailty embodies 
vulnerability to adverse effects [8]. Frailty is linked 
to a reduced vaccine effectiveness, and so important 
to consider in studies of vaccine protection [9]. 
Frailty can predict outcomes from influenza illness; 
frail elderly is more vulnerable to suffer adverse 
outcomes and less likely to return to their prior 
baseline function. 
 
It is important to differentiate between vaccine 
efficacy and vaccine effectiveness. Vaccine efficacy 
estimations are derived from research study settings, 
often randomized controlled studies, under perfect 
conditions. While, vaccine effectiveness indicates the 
benefit seen with a specific vaccine in real settings 
[10]. Surprisingly, both can be abbreviated as ‘VE’, 
therefore it is important to know to which a particular 
study is referring. It is also vital to define the 
outcomes measured in vaccine-effectiveness studies 
clearly. Several studies, from outpatient sentinel 
surveillance networks, report vaccine effectiveness 
(VE) for the prevention of medically attended 
influenza [11].  
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Vaccine effectiveness estimates could be different 
between different studies that report on the 
prevention of medically attended influenza and those 
that examine prevention of severe outcomes. A report 
from the European I-MOVE network study in the 
2016/2017 influenza season found an adjusted VE 
against medically attended influenza in primary care 
of 38.0% for all age groups; among adults, the VE 
was lower in those ≥ 65 years of age. 
 
Vaccine Effectiveness of Flu Vaccine Traditional 
Products 
Classic influenza vaccines are either split-virus or 
subunit vaccines that have distinctive antigens that 
are selected to match predicted circulating strains 
each season. The hemagglutination inhibition (HAI) 
assay is the gold-standard assay of antibody titers 
against HA and is used as a surrogate of vaccine 
efficacy for the prevention of influenza infection. 
Trivalent vaccines have 3 strain antigens (2 influenza 
A strains, A/H1 and A/H3) and one B lineage (either 
Victoria or Yamagata). 
 
While antibody responses have a major role in the 
prevention of influenza infection, cell-mediated 
immune responses play a role in both the prevention 
of infection and of serious complications of 
influenza, especially when antibody levels are low 
(as in the case of an influenza pandemic), or fail to 
prevent infection (as is often the case in older adults) 
[12].  In comparison to the usual surface protein 
vaccine targets (HA and NA), internal virus proteins 
evolve more slowly and are more often preserved 
across influenza, strains, types and subtypes, making 
them attractive potential vaccine targets. Cell-
mediated immunity, notably cytotoxic T lymphocyte 
(CTL) responses to internal viral proteins, including 
M1 and NP, is becoming more recognized as 
important in protecting against severe outcomes of 
influenza; CTLs are needed to clear influenza from 
the lungs. 
 
Irrespective of the specific details of differences in 
VE across seasons and age groups, it is obvious that 
elderly are disproportionately affected by influenza 
and its complications. 
 
Influenza and the Aging Immune System 
Functional integrity of the immune system is 
influenced by aging, presenting as reductions in 
humoral immunity, decrease in specific 
characteristics of cell-mediated immunity, and 
dysregulation of cytokine responses needed to 
activate both innate and adaptive immune 
mechanisms. Anti-inflammatory responses protect 
against damaging of the tissues effects of chronic 
inflammation linked to several chronic diseases, 
referred to as ‘inflammaging’. But, in the setting of 
acute infection like influenza, regulation of these 
inflammatory processes is requied to turn on cell-
mediated immune mechanisms and protect against 
tissue damage.  
 
Given these modifications in all aspects of the 
immune system, traditional measures of vaccine 
response such as antibody titers do not correlate well 
with strain-specific vaccine efficacy. These are 
obvious challenges for predicting responses to 
vaccination. Antibody responses are usually used to 
screen new vaccines however their limitations as sole 
predictors of vaccine efficacy are increasingly 
recognized. For example, vaccinated older adults 
who develop laboratory confirmed influenza illness 
due to A/H3N2 infection can likewise A/H3N2-
specific antibody titers following vaccination 
compared with those who do not develop laboratory 
confirmed influenza [13],  
 
There are many options that have been explored to 
date for improved influenza vaccines involving 
increasing the dose of antigen to better stimulate 
weaker adaptive responses, adding chemical agents 
(adjuvants) that promote the innate inflammatory 
response and improve the ability of dendritic cells to 
present antigen to T cells, so bringing more exposure 
to adaptive immune cells in the reactive milieu which 
ensues, and using recombinant antigens. 
 
 
Overview of Currently Available Influenza 
Vaccine Products Specifically Targeted to Older 
Adults 
3.1 High‑Dose Influenza Vaccine 
To improve the antibody response in elderly, high-
dose antigen vaccines have been created to increase 
vaccine efficacy/effectiveness. The recent high-dose 
formulation is a split-virus influenza vaccine 
(includes M1 and NP) containing 4 times the dose of 
each of the three influenza antigens in comparison 
with standard-dose trivalent vaccines. Several studies 
showed that this strategy provokes a more robust 
immune response in elderly. 
 
Significantly, this benefit was shown even in those 
older than seventy-five years of age and among 
participants with laboratory confirmed influenza 
A(H3N2) [14]. These results are furthermore 
supported by a meta-analysis of seven trials, which 
concluded a significant reduction in the risk of 
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developing laboratory-confirmed influenza among 
older persons receiving high-dose vaccine versus 
those having received standard dose. A study analysis 
of the CMS database for the 2012/2013 influenza 
season among about two million Medicare 
beneficiaries reported high-dose TIV concluded an 
overall relative effectiveness of twenty two percent 
for the prevention of laboratory-confirmed influenza. 
Benefit of the high-dose TIV in comparison to 
standard TIV appears to be greatest against influenza 
A(H3N2). In a comparative effectiveness study 
among US Medicare beneficiaries, overall relative 
effectiveness of high-dose TIV was 24% for the 
prevention of 30-day mortality following an 
emergency room visit or hospitalization with an 
administrative code for influenza over 2 influenza 
seasons. 
 
A cluster-randomized trial of US nursing home 
residents showed a reduction in risk of hospital 
admission for respiratory illness during a single 
influenza season among facilities that used high-dose 
vaccine versus those that administered standard dose. 
In spite of its higher product cost, high-dose vaccine 
has been found to be cost effective due to a reduction 
in overall influenza-related medical encounters, 
especially hospitalizations. Together, these data 
conclude that high-dose influenza vaccine decrease 
laboratory-confirmed influenza and influenza-related 
hospitalizations even among nursing home residents, 
who are more vulnerable to be frail, and is cost 
effective when compared with standard-dose 
influenza vaccine.  
 
CONCLUSIONS: 
Elderly are susceptible to poor outcomes from 
influenza in short- and long-term. Both complications 
of acute illness and continued functional disability 
have major effects on the health and well-being of 
elderly and their families. So, prevention is of highly 
importat as to support healthy elderly. Though 
immune responses to vaccination could be less 
optimal in elderly, especially those who are weak, 
vaccination remains to be an important method in the 
prevention of severe outcomes from influenza. Many 
vaccines are available for older adults, including 
standard-dose trivalent and quadrivalent formulations 
of split virus and subunit vaccines, high-dose split-
virus vaccine, adjuvanted subunit vaccine, and 
recombinant HA vaccine. Due to the relative qualities 
and availability of these products could change 
between jurisdictions, vaccinating with whatever 
proper and approved product is available continues to 
be a major recommendation; vaccination coverage 
continues to be less optimal in most states. As our 
understanding of immune changes with aging, and 
frailty progresses, vaccine products will perfectly be 
more tailored to generate optimal protection for this 
susceptible population 
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